Free shipping on all orders over $ 500


Cat. No. M1887
TG101209 Structure
Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
5mg USD 77 In stock
10mg USD 130 In stock
50mg USD 400 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
Biological Activity

TG101209, an orally bioavailable JAK2 inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. TG101209 potently inhibits JAK2 (IC(50)=6 nM), FLT3 (IC(50)=25 nM) and RET (IC(50)=17 nM) kinases, with significantly less activity against other tyrosine kinases including JAK3 (IC(50)=169 nM). TG101209 also inhibited STAT3 activation and survivin expression, and sensitized HCC2429 (DER=1.34, p=0.002) and H460 (DER=1.09, p=0.006) cells to radiation in clonogenic assays. In vivo, addition of TG101209 to radiation in lung xenografts produced a significant tumor growth delay (>10 days). TG101209 has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells.

Customer Product Validations & Biological Datas
Source J Thorac Oncol (2011). Figure 1.TG101209
Method western blots
Cell Lines HCC2429 and H460 lung cancer cells
Concentrations 1 or 3 μM
Incubation Time 24 or 48 h
Results 1 μM and 3 μM TG101209 reduced phospho- STAT3 in both cell lines while total STAT3 remained constant throughout with only a minor reduction after treatment with 3 μM TG101209 for 48 h.
Cell Experiment
Cell lines Ba/F3 cells, MPLW515L, CTLL-2 cells and HEL and K562 cells
Preparation method XTT assay for cell proliferation.
In brief, approximately 2*103 cells were plated into microtiterplate wells in 100 ml RPMI-1640 growth media with indicated concentrations of inhibitor. The relative growth of cells was quantified at 24-h intervals using Cell Proliferation Kit II (XTT) as per manufacturer’s guidelines (Roche, Indianapolis, IN, USA). After incubation, 20 ml of XTT was added to the wells and allowed to incubate for 4–6 h. The colored formazan product was measured spectrophotometrically at 450 nm with correction at 650 nm, and IC50 values were determined using the GraphPad Prism 4.0 software. Data were subjected to a non-linear regression-fit analysis and IC50 values were determined as the concentration, that inhibited proliferation by 50%. All experiments were done in triplicate and the results normalized to growth of untreated cells.
Concentrations 0~100 μ M
Incubation time 24 h
Animal Experiment
Animal models JAK2V617F-induced hematopoietic disease in a nude mouse model
Formulation DMSO
Dosages 10, 30 and 100mg/kg bid
Administration oral gavage
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 509.67
Formula C26H35N7O2S
CAS Number 936091-14-4
Purity 99.01%
Solubility DMSO 92 mg/mL
Storage at -20°C

TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells.
Ramakrishnan V, et al. Am J Hematol. 2010 Sep;85(9):675-86. PMID: 20652971.

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
Pardanani A, et al. Leukemia. 2007 Aug;21(8):1658-68. PMID: 17541402.

Related JAK Products

Peficitinib (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor, with IC50s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively.


FLLL32 is a potent JAK2/STAT3 inhibitor with IC50 of <5 μM.


WHI-P97 is a JAK3 inhibitor with an estimated Ki value of 0.09 microM from modeling studies and a measured IC50 value of 2.5 microM in EGFR kinase inhibition assays.


SAR-20347 is a potent dual inhibitor of JAK1 and TYK2 with IC50 values of 23 and 0.6 nM, respectively.


Itacitinib, also known as INCB39110 or INCB039110, is a potent JAK1 tyrosine kinase inhibitor.

Abmole Inhibitor Catalog 2017

Keywords: TG101209 supplier, JAK, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.